Walleye Capital LLC Increases Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Walleye Capital LLC lifted its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 336.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 178,007 shares of the biopharmaceutical company’s stock after buying an additional 137,201 shares during the period. Walleye Capital LLC’s holdings in ACADIA Pharmaceuticals were worth $3,266,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. R Squared Ltd purchased a new position in ACADIA Pharmaceuticals in the fourth quarter worth about $47,000. KBC Group NV lifted its stake in shares of ACADIA Pharmaceuticals by 67.0% in the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 2,044 shares during the period. Globeflex Capital L P purchased a new position in shares of ACADIA Pharmaceuticals in the fourth quarter worth approximately $168,000. Xponance Inc. bought a new stake in ACADIA Pharmaceuticals during the fourth quarter valued at approximately $186,000. Finally, Vinva Investment Management Ltd bought a new stake in ACADIA Pharmaceuticals during the fourth quarter valued at approximately $187,000. Institutional investors own 96.71% of the company’s stock.

Analysts Set New Price Targets

ACAD has been the topic of several recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Tuesday, April 8th. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Cantor Fitzgerald restated an “overweight” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft assumed coverage on ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price objective on the stock. Finally, StockNews.com raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 8th. Eight equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $23.93.

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ:ACAD opened at $14.73 on Friday. The firm has a market cap of $2.46 billion, a price-to-earnings ratio of 18.88 and a beta of 0.54. The firm has a fifty day moving average price of $17.23 and a 200 day moving average price of $16.93. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $13.40 and a fifty-two week high of $20.68.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, Director Elizabeth A. Garofalo sold 4,919 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the sale, the director now owns 17,595 shares of the company’s stock, valued at $320,756.85. The trade was a 21.85 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Mark C. Schneyer sold 3,171 shares of the stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $17.05, for a total value of $54,065.55. Following the transaction, the executive vice president now owns 56,889 shares of the company’s stock, valued at $969,957.45. This represents a 5.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,169 shares of company stock valued at $242,686 in the last 90 days. Insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.